Boschelli F - Search Results

1

Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib.

Redaelli S, Boschelli F, Perini P, Pirola A, Viltadi M, Gambacorti-Passerini C. Redaelli S, et al. Among authors: boschelli f. Leukemia. 2010 Jun;24(6):1223-7. doi: 10.1038/leu.2010.79. Epub 2010 May 6. Leukemia. 2010. PMID: 20445575 No abstract available.

2

Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.

Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, Marega M, Gambacorti-Passerini C, Boschelli F. Redaelli S, et al. Among authors: boschelli f. J Clin Oncol. 2009 Jan 20;27(3):469-71. doi: 10.1200/JCO.2008.19.8853. Epub 2008 Dec 15. J Clin Oncol. 2009. PMID: 19075254 No abstract available.

3

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.

Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, Donella-Deana A, Ahmed S, Redaelli S, Piazza R, Magistroni V, Andreoni F, Scapozza L, Formelli F, Gambacorti-Passerini C. Puttini M, et al. Among authors: boschelli f. Cancer Res. 2006 Dec 1;66(23):11314-22. doi: 10.1158/0008-5472.CAN-06-1199. Epub 2006 Nov 17. Cancer Res. 2006. PMID: 17114238

4

Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia.

Boschelli F, Arndt K, Gambacorti-Passerini C. Boschelli F, et al. Eur J Cancer. 2010 Jul;46(10):1781-9. doi: 10.1016/j.ejca.2010.02.032. Eur J Cancer. 2010. PMID: 20399641 Review.

5

In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib.

Redaelli S, Perini P, Ceccon M, Piazza R, Rigolio R, Mauri M, Boschelli F, Giannoudis A, Gambacorti-Passerini C. Redaelli S, et al. Among authors: boschelli f. J Hematol Oncol. 2015 Jul 7;8:81. doi: 10.1186/s13045-015-0179-4. J Hematol Oncol. 2015. PMID: 26149173 Free PMC article.

6

Valproic acid enhances bosutinib cytotoxicity in colon cancer cells.

Mologni L, Cleris L, Magistroni V, Piazza R, Boschelli F, Formelli F, Gambacorti-Passerini C. Mologni L, et al. Among authors: boschelli f. Int J Cancer. 2009 Apr 15;124(8):1990-6. doi: 10.1002/ijc.24158. Int J Cancer. 2009. PMID: 19123474

7

Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT).

Ozawa Y, Williams AH, Estes ML, Matsushita N, Boschelli F, Jove R, List AF. Ozawa Y, et al. Among authors: boschelli f. Leuk Res. 2008 Jun;32(6):893-903. doi: 10.1016/j.leukres.2007.11.032. Epub 2008 Jan 7. Leuk Res. 2008. PMID: 18179820

8

SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models.

Golas JM, Lucas J, Etienne C, Golas J, Discafani C, Sridharan L, Boghaert E, Arndt K, Ye F, Boschelli DH, Li F, Titsch C, Huselton C, Chaudhary I, Boschelli F. Golas JM, et al. Among authors: boschelli dh, boschelli f. Cancer Res. 2005 Jun 15;65(12):5358-64. doi: 10.1158/0008-5472.CAN-04-2484. Cancer Res. 2005. PMID: 15958584

9

SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells.

Vultur A, Buettner R, Kowolik C, Liang W, Smith D, Boschelli F, Jove R. Vultur A, et al. Among authors: boschelli f. Mol Cancer Ther. 2008 May;7(5):1185-94. doi: 10.1158/1535-7163.MCT-08-0126. Mol Cancer Ther. 2008. PMID: 18483306 Free PMC article.

10

A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.

Jallal H, Valentino ML, Chen G, Boschelli F, Ali S, Rabbani SA. Jallal H, et al. Among authors: boschelli f. Cancer Res. 2007 Feb 15;67(4):1580-8. doi: 10.1158/0008-5472.CAN-06-2027. Cancer Res. 2007. PMID: 17308097

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

61 results

Search Page

Filters